Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01684163 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 369
- Enrollment target
NCT01684163 is a Phase 2 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 369 participants.
The verdict
NCT01684163, a Phase 2 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 369 participants
- Enrollment target
Study Summary
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.
Interventions
- DRUG Placebo
- DRUG GLYX-13 5 mg/kg
- DRUG GLYX-13 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01684163
The ClinicalTrials.gov registry entry for NCT01684163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01684163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01684163 about?
NCT01684163 is a clinical study titled "Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants". GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another a...
What is the current status of trial NCT01684163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 369 participants. The study started on 2012-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01684163?
The interventions under investigation include: Placebo (DRUG), GLYX-13 5 mg/kg (DRUG), GLYX-13 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT01684163?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.